This segment focuses on the research, development, and commercialization of small molecule therapies targeting viral infections, particularly Hepatitis B virus (HBV). Assembly Biosciences utilizes its proprietary platform technologies to discover and develop drug candidates. Research and development activities include preclinical studies, clinical trials (Phase 1, 2, and potentially 3), and regulatory submissions. The company's lead product candidate, Vebicorvir, is in Phase 2 clinical trials for chronic HBV. Other candidates, such as ABI-H3733 and ABI-4334, are in earlier stages of development. The goal is to provide effective and safe treatments for patients suffering from chronic HBV, improving their liver health and reducing the risk of liver-related complications. Assembly Biosciences has collaborations with BeiGene, Ltd., Arbutus Biopharma Corporation, and Antios Therapeutics, Inc. to evaluate triple combination treatments. Future opportunities include expanding the pipeline to address other viral diseases and advancing clinical programs to later stages.